Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q4 2025 Earnings Presentation
22 slides from Arcticzymes Technologies Asa's earnings presentation, Feb 12, 2026
Slide 1: Q4 2025 Strong Quarter. Sales Growth. Improved Profitability.
February 12, 2026 Q4 2025 CEO Michael Akoh CFO Børge Sørvoll CCO Paul Blackburn Strong Quarter. Sales Growth. Improved Profitability.
Slide 2: Overview
Overview Overview AAn Norwegian biotech enzyme partner with with growthgrowth platform a scalable potential A provider of novel Customers are life World class products and Targeting segments with Worldclass Products enzymes for advanced considerable growth therapies and molecular Segment & Customers
Slide 3: Agenda
Agenda 1 Highlights Q4 and FY 2025 2 Segment performance – Biomanufacturing & Molecular Tools 3 Financials 4 Outlook and Q&A
Slide 4: Highlights Q4 and FY 2025: Strong Revenue Growth and Commercial Progress
Highlights Q4 and FY 2025: Strong Revenue Growth and Commercial Progress Q4 Total Revenue FY Revenue Metagenomics as Up 31% new long term Up 9% 34.7 MNOK growth driver 118.2 MNOK securing (26.4 MNOK) (108.1 MNOK) diversification Q4 EBITDA FY EBITDA Commercial Up 232% More than doubled organisational
Slide 5: 2025 Key Milestones & Value-Creating Events
2025 Key Milestones & Value-Creating Events Turning execution into scalable growth opportunities Solid Growth Strategy, Commercial Execution & Organizational Build-Up in Place New growth strategy facilitating scalable growth, diversification and innovation Built a stronger, scalable commercial organ
Slide 6: Sales Update Q4 2025
Sales Update Q4 2025
Slide 7: Q4 Sales - Overview
Q4 Sales - Overview High Quality Growth and Momentum Q4 2025 was our strongest quarter since Q1 2022, and the fifth-strongest quarter in the company’s 35 history 30 Importantly, this was our strongest quarter outside the peak COVID years (2020–2022) 25 Sales increased by 9.6 MNOK, representing growt
Slide 8: Q4 Sales - Biomanufacturing
Q4 Sales - Biomanufacturing Solid performance with expanding GMP adoption Biomanufacturing delivered a strong Q4, with sales of 20 15.2M NOK, representing 23% growth over Q4 2024 Growth was well balanced across channels Product performance was broad-based 15 SAN HQ M-SAN HQ Sales in MNOK 10 HL-SAN E
Slide 9: Q4 Sales - Molecular Tools
Q4 Sales - Molecular Tools Underlying business intact 25 Molecular Tools delivered a very strong quarter, with sales up 6.7M NOK to 18.9M NOK Growth was driven by significantly larger orders, with 20 average order value up 66% Order volumes and customer count were slightly 15 lower, with orders down
Slide 10: 2025 Revenues
2025 Revenues Sustained Growth Total Biomanf Mol Tools +8% +23% -5% (+26%) (+33%) 23M 26M 28M 34M
Slide 11: Sales Growth - Geography 2025
Sales Growth - Geography 2025 Territory Split EMEA -4% (39%) USA 20% (West Coast flat) APAC 17% 11
Slide 12: 2025 FY Biomanufacturing
2025 FY Biomanufacturing Growth with Quality +23% (10.7M) The majority of growth came from direct sales to CDMOs, supported by incremental contribution from resellers supplying those same customers. M-SAN was the primary growth driver, +108%, while ELISA kits grew 58%, partly reflecting new kit vali
Slide 13: 2025 Full Year Molecular Tools
2025 Full Year Molecular Tools Core Products Showing Strong Traction Cod UNG grew 31%, driven by higher demand from a small number of large strategic accounts. +2.6MNOK rSAP sales were broadly stable, with multi- customer growth offset by a decline from one large account. HL-dsDNase declined 28% rep
Slide 14: Project Driven Momentum
Project Driven Momentum Building Momentum Through Conversion (12M average) 30 000 29 000 28 000 27 000 26 000 25 000 24 000 23 000 22 000 21 000 20 000 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Total 16 000 8 500 15 000 8 000 14 000 7 500 13 000 7 000 12 000 6 500 11 000 6 000
Slide 15: Expenses & Profitability
® OF Expenses & Profitability ae “X% ge ~e
Slide 16: Currency impact
USD/NOK Currency impact 12 11,5 Significant Growth despite headwinds 11 10,5 10 • Norwegian krone strengthened against the USD 9,5 with almost 10% from last year 9 • Euro unchanged from last year 8,5 2024 2025 Adjusting Q4 2025 revenues Q4 for 2025constant Adj currency: Change EUR/NOK 12,2 34.1 MNOK
Slide 17: Profit and loss - Expense development
Profit and loss - Expense development Cost Control Resulting in Normalised expense levels Q4 YTD Personnel expenses 2025 2024 2025 2024 Reduced capitalisation Sales revenues 34,1 24,5 112,6 104,4 Other revenues 0,6 1,9 5,6 3,7 Reversed 1,9 MNOK in accrued Sum revenues 34,7 26,4 118,3 108,1 commissio
Slide 18: Profitability and expenses
Profitability and expenses Trend for 2025 continues Sales & EBITDA Q4 YTD 2025 2024 2025 2024 35 Sales Sales revenues 34,1 24,5 112,6 104,4 EBITDA Other revenues 0,6 1,9 5,6 3,7 30 Sum revenues 34,7 26,4 118,3 108,1 25 Cost of materials -1,7 -1,7 -4,4 -9,0 Change in inventory 0,1 0,2 -0,3 3,0 20 Per
Slide 19: Cash flow and short-term investments
Cash flow and short-term investments 6.4 MNOK in changes for Q4* - FY 2025 20.8 MNOK Cash and STI position 280 Short term investments (STI) Net Cash (MNOK) 30 Changes in Cash and STI (MNOK) 25 260 20 240 Changes in cash and STI (MNOK) 15 Net Cash (MNOK) 220 10 200 5 180 0 160 -5 140 -10 Q1 2024 Q2 2
Slide 20: Outlook 2026
Outlook 2026 ArcticZymes enters 2026 with momentum and a strengthened platform Biomanufacturing • Scale GMP-grade nuclease adoption for late-stage manufacturing • Deeper and broader CDMO collaborations • Brenntag partnership in Europe and channel partnerships in ROW Molecular Tools • Sustain momentu
Slide 21: Capital Markets Day - March 6, 2026
Capital Markets Day - March 6, 2026 – 9:00-12:00 Nordea: Smålandsgatan 17, Stockholm, Sweden or Virtually From transformation to scalable growth The Strategy A focused growth strategy built on customer-centric execution, innovation, diversification and operational scalability The Markets Where Arcti
Slide 22: Thank you Q & A
ArcticZymes Technologies *
ArcticZymes Technologies — Q4 2025 Earnings Presentation on 6ix